|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions decreases expression |
ISO |
Methotrexate inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of ABCA1 mRNA]; ZM 241385 inhibits the reaction [Methotrexate inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of ABCA1 mRNA]] |
CTD |
PMID:19035488 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
decreases expression increases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of ABCB1 mRNA; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of ABCB1 protein N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of ABCB1 mRNA |
CTD |
PMID:21745461 PMID:23466342 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
increases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of ABCC1 mRNA |
CTD |
PMID:21745461 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [VEGFA protein results in increased expression of ACE protein] |
CTD |
PMID:11158990 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ACTA2 protein] |
CTD |
PMID:27697457 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [AGT protein results in increased abundance of Prostaglandins E] |
CTD |
PMID:19145780 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
multiple interactions increases activity increases expression |
ISO |
[N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of ALOX15 protein] which results in increased chemical synthesis of 13-hydroxy-9,11-octadecadienoic acid; caffeic acid inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased activity of ALOX15 protein]; GATA6 protein inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of ALOX15 protein] N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of ALOX15 mRNA; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of ALOX15 protein |
CTD |
PMID:10904086 PMID:11406566 PMID:11861401 |
|
NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874
|
|
G |
Arg1 |
arginase 1 |
multiple interactions |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in decreased expression of ARG1 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [IL4 protein results in increased expression of ARG1 mRNA] |
CTD |
PMID:26748080 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Atp6ap2 |
ATPase H+ transporting accessory protein 2 |
multiple interactions |
EXP |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Glucose results in increased expression of ATP6AP2 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Glucose results in increased expression of ATP6AP2 protein] |
CTD |
PMID:19861503 |
|
NCBI chr X:10,183,983...10,210,948
Ensembl chr X:10,183,068...10,210,918
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
[N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide co-treated with rosiglitazone] results in increased expression of BAX mRNA; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide co-treated with rosiglitazone] results in increased expression of BAX protein N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of BAX mRNA; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of BAX protein |
CTD |
PMID:19056168 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO |
[N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide co-treated with rosiglitazone] results in decreased expression of BCL2 mRNA; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide co-treated with rosiglitazone] results in decreased expression of BCL2 protein N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [Dihematoporphyrin Ether results in increased cleavage of BCL2 protein] N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of BCL2 mRNA; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of BCL2 protein |
CTD |
PMID:16230411 PMID:19056168 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Capn1 |
calpain 1 |
decreases expression |
EXP |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of CAPN1 protein |
CTD |
PMID:28342779 |
|
NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177
|
|
G |
Capn2 |
calpain 2 |
decreases expression |
EXP |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of CAPN2 protein |
CTD |
PMID:28342779 |
|
NCBI chr13:94,150,244...94,200,969
Ensembl chr13:94,150,240...94,200,969
|
|
G |
Casp2 |
caspase 2 |
multiple interactions |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [resveratrol results in increased expression of CASP2 mRNA]; SUMO1 protein affects the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [resveratrol results in increased expression of CASP2 mRNA]] |
CTD |
PMID:29242151 |
|
NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO EXP |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; PTGS2 protein inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased activity of CASP3 protein] N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [[sodium bisulfite co-treated with sodium sulfite] results in increased cleavage of CASP3 protein] N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased cleavage of CASP3 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [cadmium sulfate results in increased activity of CASP3 protein] |
CTD |
PMID:12414664 PMID:14687664 PMID:21745461 PMID:21873648 PMID:32115946 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [cadmium sulfate results in increased activity of CASP7 protein] |
CTD |
PMID:14687664 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased activity of CASP8 protein |
CTD |
PMID:12414664 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity multiple interactions |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased activity of CASP9 protein PTGS2 protein inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased activity of CASP9 protein] |
CTD |
PMID:12414664 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions decreases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [CAT protein results in decreased abundance of Dinoprostone] N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of CAT protein |
CTD |
PMID:10899936 PMID:18848576 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cav1 |
caveolin 1 |
decreases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of CAV1 protein |
CTD |
PMID:18848576 |
|
NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [IL1A protein results in increased secretion of CCL2 protein]]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [TNF protein results in increased secretion of CCL2 protein]]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [IL1A protein results in increased secretion of CCL2 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [macrophage stimulatory lipopeptide 2 results in increased secretion of CCL2 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [TNF protein results in increased secretion of CCL2 protein] |
CTD |
PMID:11230753 PMID:18096868 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of CCNB1 protein |
CTD |
PMID:11504793 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression multiple interactions |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of CCND1 mRNA; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of CCND1 protein N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [resveratrol results in decreased expression of CCND1 mRNA]; SUMO1 protein affects the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [resveratrol results in decreased expression of CCND1 mRNA]]; SUMO1 protein affects the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of CCND1 mRNA] |
CTD |
PMID:11504793 PMID:29242151 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccne2 |
cyclin E2 |
multiple interactions |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [VEGFC protein results in increased expression of CCNE2 protein] |
CTD |
PMID:24184161 |
|
NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632
|
|
G |
Ccnk |
cyclin K |
decreases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of CCNK mRNA |
CTD |
PMID:11494140 |
|
NCBI chr 6:127,090,115...127,113,195
Ensembl chr 6:127,090,569...127,113,191
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases activity multiple interactions |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of CDK2 protein N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [VEGFC protein results in increased expression of CDK2 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [CDKN1A protein results in decreased activity of CDK2 protein]; PTGS2 protein affects the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of CDK2 protein] |
CTD |
PMID:14566837 PMID:24184161 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression increases activity multiple interactions |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of CDKN1A mRNA; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of CDKN1A protein N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased activity of CDKN1A protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of CDKN1A mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [CDKN1A protein results in decreased activity of CDK2 protein] |
CTD |
PMID:14566837 PMID:14567460 PMID:16376453 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression multiple interactions |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of CDKN1B protein N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [VEGFC protein results in decreased expression of CDKN1B protein] |
CTD |
PMID:14567460 PMID:24184161 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Chrna4 |
cholinergic receptor nicotinic alpha 4 subunit |
increases expression multiple interactions |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of CHRNA4 protein [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide co-treated with Nicotine] inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of CHRNA4 protein] |
CTD |
PMID:15551346 |
|
NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957
|
|
G |
Chrnb4 |
cholinergic receptor nicotinic beta 4 subunit |
increases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of CHRNB4 protein |
CTD |
PMID:15551346 |
|
NCBI chr 8:55,417,583...55,437,027
Ensembl chr 8:55,418,313...55,437,027
|
|
G |
Col10a1 |
collagen type X alpha 1 chain |
multiple interactions |
ISO |
[N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased expression of COL10A1 mRNA; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased expression of COL10A1 protein |
CTD |
PMID:27050768 |
|
NCBI chr20:38,183,103...38,189,488
Ensembl chr20:38,182,494...38,189,494
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [nickel sulfate inhibits the reaction [macrophage stimulatory lipopeptide 2 results in increased secretion of CXCL10 protein]] |
CTD |
PMID:18096868 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
multiple interactions decreases activity decreases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [LEP protein results in increased expression of CYP19A1 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [LEP protein results in increased expression of CYP19A1 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [o,p'-DDT results in increased expression of CYP19A1 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [o,p'-DDT results in increased expression of CYP19A1 protein] N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide analog results in decreased activity of CYP19A1 protein; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of CYP19A1 protein N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide analog results in decreased expression of CYP19A1 mRNA; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of CYP19A1 mRNA |
CTD |
PMID:15964185 PMID:16480277 PMID:20678559 PMID:28571770 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 protein] |
CTD |
PMID:20093341 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
multiple interactions decreases expression |
ISO |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of CYP27A1 mRNA]; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of CYP27A1 protein]; Methotrexate inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of CYP27A1 mRNA]; Methotrexate inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of CYP27A1 protein]; ZM 241385 inhibits the reaction [Methotrexate inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of CYP27A1 mRNA]] N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of CYP27A1 mRNA; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of CYP27A1 protein |
CTD |
PMID:19035488 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
decreases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of DDIT3 protein |
CTD |
PMID:17709599 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dnm2 |
dynamin 2 |
increases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of DNM2 mRNA |
CTD |
PMID:11494140 |
|
NCBI chr 8:19,978,313...20,060,162
Ensembl chr 8:19,978,400...20,060,157
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [VEGFA protein results in increased expression of EGR1 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [VEGFA protein results in increased expression of EGR1 protein] |
CTD |
PMID:11595463 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
F2 |
coagulation factor II, thrombin |
decreases activity multiple interactions |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of F2 N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [F2 protein results in increased abundance of Thromboxane A2 metabolite]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [F2 protein results in increased abundance of Thromboxane B2] |
CTD |
PMID:10027849 PMID:17379757 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
[sodium arsenite co-treated with N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide] results in increased localization of and results in increased stability of FASLG protein |
CTD |
PMID:16487513 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fat1 |
FAT atypical cadherin 1 |
increases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of FAT1 mRNA |
CTD |
PMID:11494140 |
|
NCBI chr16:47,177,253...47,296,261
Ensembl chr16:47,177,248...47,296,107
|
|
G |
Flg |
filaggrin |
multiple interactions |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Particulate Matter results in decreased expression of FLG protein] |
CTD |
PMID:31884678 |
|
NCBI chr 2:178,884,793...178,912,986
|
|
G |
Gata6 |
GATA binding protein 6 |
multiple interactions decreases expression |
ISO |
GATA6 protein inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of ALOX15 protein] N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of GATA6 protein |
CTD |
PMID:11861401 |
|
NCBI chr18:2,188,121...2,219,532
Ensembl chr18:2,188,121...2,219,532
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of GDF15 protein |
CTD |
PMID:15180942 |
|
NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of GPX1 protein |
CTD |
PMID:18848576 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions |
EXP |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Sulfur Dioxide results in increased cleavage of GRIN2B protein] |
CTD |
PMID:21873648 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Etoposide results in increased phosphorylation of H2AX protein] |
CTD |
PMID:21745461 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
Hgf |
hepatocyte growth factor |
multiple interactions decreases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [HGF results in increased activity of MAPK1 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [HGF results in increased activity of MAPK3 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [HGF results in increased expression of MMP9] N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of HGF mRNA |
CTD |
PMID:10807402 PMID:11981761 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein] |
CTD |
PMID:16527254 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO EXP |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Zymosan results in increased expression of HMOX1 protein] N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [arsenic trioxide results in increased expression of HMOX1] N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Pravastatin results in increased expression of HMOX1 protein] |
CTD |
PMID:11454666 PMID:20368269 PMID:23649692 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
Dinoprostone inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Cadmium Chloride results in increased expression of ICAM1 mRNA]]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Cadmium Chloride results in increased expression of ICAM1 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Cadmium Chloride results in increased expression of ICAM1 protein] |
CTD |
PMID:16777358 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased abundance of Dinoprostone] N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of PTGS2 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in decreased expression of ARG1 mRNA] |
CTD |
PMID:12911628 PMID:26748080 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Dihematoporphyrin Ether results in decreased expression of IL10 protein] |
CTD |
PMID:16230411 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [IL1A protein results in increased secretion of CCL2 protein]]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [IL1A protein results in increased abundance of Dinoprostone]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [IL1A protein results in increased secretion of CCL2 protein] |
CTD |
PMID:11230753 PMID:15167967 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression |
ISO EXP |
Dexamethasone inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of [IL1B protein results in increased expression of PTGS2 protein]]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [cobaltous chloride results in increased secretion of IL1B protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [IL1B protein results in increased abundance of Dinoprost]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of IL1B protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Silicon Dioxide results in increased secretion of IL1B protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Zymosan analog results in increased expression of IL1B protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [IL1B protein results in increased expression of PTGS2 mRNA] N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [Acetic Acid results in increased expression of IL1B protein] |
CTD |
PMID:11286988 PMID:11376495 PMID:12517972 PMID:12946449 PMID:16354411 PMID:19580863 PMID:21779360 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [IL4 protein results in increased expression of ARG1 mRNA] |
CTD |
PMID:26748080 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
decreases expression multiple interactions |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of IL6 mRNA [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [cobaltous chloride results in increased secretion of IL6 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [cobaltous chloride results in increased secretion of IL6 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of IL6 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Silicon Dioxide results in increased secretion of IL6 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Zymosan analog results in increased expression of IL6 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [deoxynivalenol results in increased expression of IL6 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [deoxynivalenol results in increased expression of IL6 protein] |
CTD |
PMID:12649040 PMID:12946449 PMID:15379866 PMID:17709599 PMID:19580863 PMID:21533553 PMID:21779360 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins2 |
insulin 2 |
multiple interactions increases secretion |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [Arachidonic Acid results in increased secretion of INS protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [Glucose results in increased secretion of INS protein] N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased secretion of INS protein |
CTD |
PMID:17192482 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [LEP protein results in increased expression of CYP19A1 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [LEP protein results in increased expression of CYP19A1 protein] |
CTD |
PMID:28571770 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased phosphorylation of MAPK1 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of MAPK1 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [HGF results in increased activity of MAPK1 protein] N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [resveratrol promotes the reaction [MAPK1 protein binds to PTGS2 protein]] |
CTD |
PMID:11981761 PMID:16376453 PMID:17984113 PMID:26358519 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased phosphorylation of MAPK3 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of MAPK3 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [HGF results in increased activity of MAPK3 protein] N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [resveratrol promotes the reaction [MAPK3 protein binds to PTGS2 protein]] |
CTD |
PMID:11981761 PMID:16376453 PMID:17984113 PMID:26358519 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of MKI67 mRNA |
CTD |
PMID:27318970 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [anandamide results in increased expression of MMP9 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Dronabinol results in increased expression of MMP9 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [HGF results in increased expression of MMP9]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [methanandamide results in increased expression of MMP9 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [methanandamide results in increased expression of MMP9 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MMP9 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA] |
CTD |
PMID:11981761 PMID:16330497 PMID:19804834 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [resveratrol results in decreased expression of MYC mRNA]; SUMO1 protein affects the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [resveratrol results in decreased expression of MYC mRNA]] |
CTD |
PMID:29242151 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
decreases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of NFKBIA protein |
CTD |
PMID:12517972 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA] |
CTD |
PMID:26748080 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [Dihematoporphyrin Ether results in increased cleavage of PARP1 protein] |
CTD |
PMID:16230411 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pawr |
pro-apoptotic WT1 regulator |
increases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of PAWR mRNA |
CTD |
PMID:10833474 |
|
NCBI chr 7:43,645,028...43,725,033
Ensembl chr 7:43,645,084...43,725,028
|
|
G |
Pcdh7 |
protocadherin 7 |
increases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of PCDH7 mRNA |
CTD |
PMID:11494140 |
|
NCBI chr14:52,471,801...52,901,696
Ensembl chr14:52,475,610...52,902,051 Ensembl chr14:52,475,610...52,902,051
|
|
G |
Pclaf |
PCNA clamp associated factor |
decreases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of PCLAF mRNA |
CTD |
PMID:11494140 |
|
NCBI chr 8:66,420,606...66,432,994
Ensembl chr 8:66,420,587...66,432,994 Ensembl chr 8:66,420,587...66,432,994
|
|
G |
Pdcd4 |
programmed cell death 4 |
increases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of PDCD4 mRNA |
CTD |
PMID:11494140 |
|
NCBI chr 1:252,921,342...252,944,278
Ensembl chr 1:252,921,392...252,944,275
|
|
G |
Pdgfa |
platelet derived growth factor subunit A |
multiple interactions |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [PDGFA results in increased abundance of Dinoprostone]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [PDGFA results in increased abundance of Epoprostenol] |
CTD |
PMID:19201774 |
|
NCBI chr12:15,645,549...15,667,056
Ensembl chr12:15,645,541...15,666,497
|
|
G |
Pdlim5 |
PDZ and LIM domain 5 |
increases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of PDLIM5 mRNA |
CTD |
PMID:11494140 |
|
NCBI chr 2:230,952,251...231,120,329
Ensembl chr 2:230,952,248...231,120,275
|
|
G |
Pomc |
proopiomelanocortin |
multiple interactions |
EXP |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [docetaxel results in increased expression of POMC mRNA] |
CTD |
PMID:22902858 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions decreases expression |
ISO EXP |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [ciglitazone results in increased expression of PPARA mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [pirinixic acid results in increased expression of PPARA mRNA] N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Pravastatin affects the localization of PPARA protein] N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of PPARA mRNA |
CTD |
PMID:11840453 PMID:20368269 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases localization decreases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Cannabidiol affects the localization of PPARG protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Celecoxib affects the localization of PPARG protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [ciglitazone results in increased expression of PPARG mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Lovastatin analog affects the localization of PPARG protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [pirinixic acid results in increased expression of PPARG mRNA] N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased localization of PPARG protein N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of PPARG mRNA |
CTD |
PMID:11840453 PMID:12517972 PMID:23220503 PMID:23943857 PMID:26863638 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppfia1 |
PTPRF interacting protein alpha 1 |
increases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of PPFIA1 mRNA |
CTD |
PMID:11494140 |
|
NCBI chr 1:199,641,277...199,718,371
Ensembl chr 1:199,641,277...199,717,277
|
|
G |
Ptger2 |
prostaglandin E receptor 2 |
multiple interactions decreases expression |
EXP ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Sulfur Dioxide results in increased expression of PTGER2 protein] N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of PTGER2 protein] N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of PTGER2 protein |
CTD |
PMID:17709599 PMID:21873648 PMID:32115946 |
|
NCBI chr15:18,215,013...18,228,714
Ensembl chr15:18,217,285...18,228,714
|
|
G |
Ptger4 |
prostaglandin E receptor 4 |
multiple interactions |
EXP ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Sulfur Dioxide results in increased expression of PTGER4 protein] N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of PTGER4 protein] |
CTD |
PMID:21873648 PMID:32115946 |
|
NCBI chr 2:54,330,563...54,347,451
Ensembl chr 2:54,335,424...54,346,670
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
decreases activity multiple interactions |
ISO EXP |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS1 protein N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [Cadmium Chloride results in increased expression of PTGS1 mRNA] [SC 560 results in decreased activity of PTGS1 protein] promotes the reaction [[N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [[sodium bisulfite co-treated with sodium sulfite] results in increased abundance of Dinoprostone]] |
CTD |
PMID:9258749 PMID:15155531 PMID:15843042 PMID:21873648 PMID:25645360 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases activity multiple interactions increases response to substance increases expression increases activity decreases expression |
ISO EXP |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [trans-10,cis-12-conjugated linoleic acid results in increased chemical synthesis of Dinoprost]; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprost; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased abundance of Thromboxane A2; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased expression of COL10A1 mRNA; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased expression of COL10A1 protein; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased expression of RUNX2 mRNA; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased expression of RUNX2 protein; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of PTGS2 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of PTGS2 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Benzo(a)pyrene results in increased expression of PTGS2 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Dibutyl Phthalate results in increased expression of PTGS2 protein] [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide binds to and results in decreased activity of PTGS2 protein] which results in decreased susceptibility to Streptozocin; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [[sodium bisulfite co-treated with sodium sulfite] results in increased abundance of Cyclic AMP]; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [[sodium bisulfite co-treated with sodium sulfite] results in increased abundance of Dinoprostone]; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprost; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of Dinoprostone; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased secretion of Dinoprost; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased secretion of Dinoprostone; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased susceptibility to Lipopolysaccharides; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased susceptibility to Norepinephrine; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased susceptibility to VX; [SC 560 results in decreased activity of PTGS1 protein] promotes the reaction [[N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [[sodium bisulfite co-treated with sodium sulfite] results in increased abundance of Dinoprostone]]; Dinoprostone results in decreased susceptibility to [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein]; Ketorolac inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [Carrageenan results in increased expression of PTGS2 protein]]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [[sodium bisulfite co-treated with sodium sulfite] results in increased expression of PTGS2 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [PTGS2 protein results in increased abundance of Dinoprost]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Resveratrol promotes the reaction [MAPK1 protein binds to PTGS2 protein]]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Resveratrol promotes the reaction [MAPK3 protein binds to PTGS2 protein]]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [Carrageenan results in increased expression of PTGS2 protein] PTGS2 protein results in increased susceptibility to N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of [IL1B protein results in increased expression of PTGS2 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of PTGS2 mRNA; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of PTGS2 protein N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased activity of PTGS2 protein N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of PTGS2; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of PTGS2 mRNA; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of PTGS2 protein [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide co-treated with [Vanadates results in increased abundance of Vanadium]] results in increased expression of PTGS2 protein; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [Ceramides results in increased phosphorylation of TP53 protein]; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [CGB3 protein results in increased chemical synthesis of Dinoprost]; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [cobaltous chloride results in increased secretion of CXCL8 protein]; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [cobaltous chloride results in increased secretion of IL6 protein]; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [Resveratrol results in increased activity of TP53 protein]; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which affects the susceptibility to Dinitrofluorobenzene; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased susceptibility to Ceramides; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased susceptibility to o,p'-DDT; Dexamethasone inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of [IL1B protein results in increased expression of PTGS2 protein]]; Dexamethasone inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of and results in increased activity of PTGS2 protein]; Dinoprostone inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprostone]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [[Tetradecanoylphorbol Acetate results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Cadmium Chloride results in increased expression of PTGS2 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Celecoxib results in increased activity of PTGS2 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [cumene hydroperoxide results in increased expression of PTGS2 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Resveratrol results in increased expression of PTGS2 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Resveratrol results in increased expression of PTGS2 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [VEGFA protein results in increased expression of PTGS2 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [VEGFA protein results in increased expression of PTGS2 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of and results in increased activity of PTGS2 protein; PTGS2 protein affects the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of CDK2 protein]; PTGS2 protein inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased activity of CASP3 protein]; PTGS2 protein inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased activity of CASP9 protein]; SUMO1 protein affects the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Resveratrol results in increased expression of PTGS2 mRNA]] |
CTD |
PMID:9258749 PMID:9705326 PMID:10485483 PMID:10594344 PMID:10791687 PMID:11059772 PMID:11095985 PMID:11321505 PMID:11494140 PMID:12414664 PMID:12417326 PMID:12517972 PMID:12970750 PMID:14566837 PMID:14726416 PMID:14972014 PMID:15144595 PMID:15155531 PMID:15834289 PMID:15843042 PMID:16098373 PMID:16396944 PMID:16928824 PMID:17112505 PMID:17258197 PMID:17709599 PMID:17984113 PMID:18202791 PMID:18446786 PMID:18555068 PMID:18596194 PMID:18848576 PMID:19014992 PMID:20678559 PMID:20826536 PMID:21362464 PMID:21533553 PMID:21873648 PMID:22306367 PMID:22583689 PMID:23495037 PMID:23943857 PMID:25398544 PMID:25645360 PMID:26748080 PMID:27050768 PMID:29242151 PMID:30291943 PMID:32115946 PMID:32738273 PMID:35605887 More...
|
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions |
ISO |
[N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased expression of RUNX2 mRNA; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased expression of RUNX2 protein |
CTD |
PMID:27050768 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions decreases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein] N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of SOD2 protein |
CTD |
PMID:12031898 PMID:18848576 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sumo1 |
small ubiquitin-like modifier 1 |
multiple interactions |
ISO |
SUMO1 protein affects the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [resveratrol results in decreased expression of CCND1 mRNA]]; SUMO1 protein affects the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [resveratrol results in decreased expression of MYC mRNA]]; SUMO1 protein affects the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [resveratrol results in increased expression of CASP2 mRNA]]; SUMO1 protein affects the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [resveratrol results in increased expression of PTGS2 mRNA]]; SUMO1 protein affects the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of CCND1 mRNA] |
CTD |
PMID:29242151 |
|
NCBI chr 9:61,078,790...61,108,697
Ensembl chr 9:61,077,435...61,108,761
|
|
G |
Tac1 |
tachykinin, precursor 1 |
multiple interactions |
EXP |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [GR 73632 promotes the reaction [Capsaicin results in increased secretion of TAC1 protein]] |
CTD |
PMID:18809416 |
|
NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Cisplatin results in increased expression of TGFB1 mRNA] |
CTD |
PMID:21256724 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [anandamide results in increased expression of TIMP1 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Dronabinol results in increased expression of TIMP1 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [methanandamide results in increased expression of TIMP1 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [methanandamide results in increased expression of TIMP1 protein] |
CTD |
PMID:16330497 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [TNF protein results in increased secretion of CCL2 protein]]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [TNF protein results in increased secretion of CCL2 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein] N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [Acetic Acid results in increased expression of TNF protein] N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [TNF protein results in increased abundance of Dinoprostone] |
CTD |
PMID:9576062 PMID:11230753 PMID:11376495 PMID:15379866 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf10b |
TNF receptor superfamily member 10b |
increases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of TNFRSF10A protein |
CTD |
PMID:15572759 |
|
NCBI chr15:44,840,386...44,868,318
Ensembl chr15:44,840,386...44,867,467
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
multiple interactions |
ISO |
[N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [sodium arsenite results in increased expression of and results in increased localization of TNFRSF10B protein]] results in increased susceptibility to [TNFSF10 protein co-treated with Cycloheximide]; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [sodium arsenite results in increased expression of and results in increased localization of TNFRSF10B protein]] results in increased susceptibility to [TNFSF10 protein co-treated with resveratrol] |
CTD |
PMID:18222423 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions decreases expression |
ISO EXP |
[N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [Ceramides results in increased phosphorylation of TP53 protein]; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [resveratrol results in increased activity of TP53 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [resveratrol results in increased expression of TP53 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [resveratrol results in increased phosphorylation of TP53 protein] N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of TP53 mRNA |
CTD |
PMID:16928824 PMID:17984113 PMID:18446786 PMID:23495037 PMID:29242151 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tpx2 |
TPX2, microtubule nucleation factor |
decreases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of TPX2 mRNA |
CTD |
PMID:11494140 |
|
NCBI chr 3:141,318,428...141,360,684
Ensembl chr 3:141,318,455...141,360,468
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions |
EXP |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [GR 73632 results in increased phosphorylation of TRPV1 protein] |
CTD |
PMID:18809416 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [VEGFA protein results in increased expression of EGR1 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [VEGFA protein results in increased expression of EGR1 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [VEGFA protein results in increased expression of PTGS2 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [VEGFA protein results in increased expression of PTGS2 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [VEGFA protein results in increased expression of ACE protein] |
CTD |
PMID:11158990 PMID:11595463 PMID:18596194 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vegfc |
vascular endothelial growth factor C |
multiple interactions |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [VEGFC protein results in decreased expression of CDKN1B protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [VEGFC protein results in increased expression of CCNE2 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [VEGFC protein results in increased expression of CDK2 protein] |
CTD |
PMID:24184161 |
|
NCBI chr16:37,712,251...37,827,845
Ensembl chr16:37,712,262...37,827,848
|
|